Trial Profile
Safety and tolerability of BPM-31510 (ubidecarenone) in patients with advanced solid tumors
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 07 Aug 2015
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 07 Aug 2015 New trial record
- 22 Apr 2015 Results in 56 patients presented at the 106th Annual Meeting of the American Association for Cancer Research.